Overview

• NHS England will offer wearable drug pumps to up to 1,000 advanced Parkinson's patients, replacing the need to take up to 20 tablets a day.
• The portable infusion devices deliver foslevodopa-foscarbidopa directly into the bloodstream, enhancing movement control and reducing side effects.
• Eligible patients include those with severe motor fluctuations and who are not responding to oral treatments, with rollout expected in the coming weeks.
• Clinical trials have shown the treatment to be safe and effective, with patients reporting significant improvements in symptom management and quality of life.
• Parkinson's UK hails the introduction of the wearable pumps as a life-changing option, though it may not be suitable for all patients.